Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 724 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mild Dementia Clear all
Not listed Phase 2 Interventional

Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease

NCT03625401
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
AD-35 60mg group, Placebo group
Drug
Lead sponsor
Zhejiang Hisun Pharmaceutical Co. Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Sacramento, California • San Diego, California • Delray Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 21, 2026, 7:01 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

NCT05619692
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
Interventions
SAGE-718, SAGE-718-matching Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
37
States / cities
Gilbert, Arizona • Phoenix, Arizona • Lafayette, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 21, 2026, 7:01 PM EDT
Completed Phase 2 Interventional

Exercise Treatment of Mild-Stage Probable Alzheimer's Disease

NCT00403507
View directory record Official record
Conditions
Alzheimer Disease, Memory Disorders, Dementia
Interventions
Participation in a monitored exercise program, Personalized aerobic and strength training.
Behavioral
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
65 Years to 89 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced Oct 21, 2026, 7:01 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

NCT02727699
View directory record Official record
Conditions
Dementia, Alzheimer Type
Interventions
Xanamem™, Placebo (for Xanamem™)
Drug
Lead sponsor
Actinogen Medical
Industry
Eligibility
50 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Poway, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 21, 2026, 7:01 PM EDT
Completed Early Phase 1 Interventional

Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients

NCT01659398
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
External Counterpulsation (EECP)
Device
Lead sponsor
Patrick Moriarty, MD, FACP, FACC
Other
Eligibility
18 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 21, 2026, 7:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Olfactory Deficits in Neurologic Disease

NCT05019014
View directory record Official record
Conditions
Alzheimer Disease, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Lewy Body Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 21, 2026, 7:01 PM EDT
Completed Not applicable Interventional

My Healthy Brain: Preserving and Promoting Brain Health Through Evidence-based Practices

NCT04537728
View directory record Official record
Conditions
Aging, Mild Cognitive Impairment, Dementia, Old Age; Dementia, Cognitive Decline
Interventions
My Healthy Brain Version 2
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 21, 2026, 7:01 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

NCT03639987
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer's Disease
Interventions
Aducanumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 21, 2026, 7:01 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

NCT01908010
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-354, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 21, 2026, 7:01 PM EDT
Completed Phase 3 Interventional Results available

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease

NCT00348140
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
49
States / cities
Sun City, Arizona • Tucson, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 21, 2026, 7:01 PM EDT
Completed Not applicable Interventional Results available

Indiana University Dementia Screening Trial

NCT01699503
View directory record Official record
Conditions
Dementia, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Collaborative Dementia Care Program
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older
Enrollment
4,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Indianapolis, Indiana • West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 21, 2026, 7:01 PM EDT
Terminated Phase 2 Interventional Results available

A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

NCT03919162
View directory record Official record
Conditions
Alzheimer Disease
Interventions
PQ912, Placebo
Drug · Other
Lead sponsor
Vivoryon Therapeutics N.V.
Industry
Eligibility
50 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Chula Vista, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 21, 2026, 7:01 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease

NCT03089827
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2031
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 21, 2026, 7:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Risk Evaluation and Education for Alzheimer's Disease

NCT00571025
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
APOE Disclosure
Behavioral
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 85 Years
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2009 · Synced Oct 21, 2026, 7:01 PM EDT
Recruiting Not applicable Interventional

δ in Dementia Clinical Trials

NCT05592678
View directory record Official record
Conditions
Alzheimer's Disease (AD), Dementia, Cognitive Decline, Mild Cognitivie Impairment (MCI)
Interventions
Donepezil
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 21, 2026, 7:01 PM EDT
Completed Phase 2 Interventional Results available

Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

NCT00040443
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
CX516, Placebo
Drug
Lead sponsor
RespireRx
Industry
Eligibility
55 Years to 85 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
8
States / cities
Peoria, Arizona • Irvine, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 21, 2026, 7:01 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Trontinemab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Sun City, Arizona • Irvine, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 7:01 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Goal Setting to Promote Physical Activity Adherence in Midlife Adults

NCT05980052
View directory record Official record
Conditions
Physical Activity, Exercise
Interventions
Physical Activity
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
45 Years to 65 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 7:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Memory in Mild Cognitive Impairment and Early Stage Alzheimer's Disease

NCT05077826
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
North Coast Medical Activadose II
Device
Lead sponsor
The Mind Research Network
Other
Eligibility
50 Years to 90 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 21, 2026, 7:01 PM EDT
Completed Phase 2 Interventional Results available

Effects of Atomoxetine in Mild Cognitive Impairment

NCT01522404
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 21, 2026, 7:01 PM EDT
Terminated Phase 2 Interventional Results available

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

NCT02322021
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Alzheimer Type
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
21
States / cities
Bellflower, California • Costa Mesa, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 21, 2026, 7:01 PM EDT
Enrolling by invitation Phase 4 Interventional

DaTSCAN Imaging in Aging and Neurodegenerative Disease

NCT01453127
View directory record Official record
Conditions
Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
Interventions
I-123 Ioflupane solution injection prior to SPECT scan (DaTscan), Single photon emission computed tomography (SPECT) scan
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 21, 2026, 7:01 PM EDT
Completed Phase 1 Interventional

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease

NCT01966666
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TPI-287 2 mg/m2, TPI-287 6.3 mg/m2, TPI-287 20 mg/m2, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 82 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 21, 2026, 7:01 PM EDT
Completed No phase listed Observational

New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study

NCT04426539
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
American College of Radiology
Other
Eligibility
18 Years and older
Enrollment
6,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 21, 2026, 7:01 PM EDT